Autopsy report · NCT04656691

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

“In April 2021 FDA revoked the Emergency Use Authorization after determining that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 months before it stopped.
• 139 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Daniel Griffin

Sponsor type

Industry

Conditions

Covid19

Interventions

bamlanivimab

Participants

139

Sites

1

Countries

United States

Trials that died the same way

• Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
  “Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.